The World In A Grain Of Sand

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive into: Base editing, and its adva

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Patrick Malone and Mack Healy discuss the biopharma software juggernaut, Schrödinger. We dive into: Schrödinger's biophysics-based drug discovery platform, and the distinction from machine

KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss: the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive

KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Codiak BioSciences.

KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Royalty Pharma.

KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Sana Biotechnology.

KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Editas.

KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Century Therapeutics.

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Taysha GTx

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Atai